Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

MLA

Martin, Miguel, et al. “Neratinib after Trastuzumab-Based Adjuvant Therapy in HER2-Positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” The Lancet. Oncology, vol. 18, no. 12, Dec. 2017, pp. 1688–700. EBSCOhost, https://doi.org/10.1016/S1470-2045(17)30717-9.

APA

Martin, M., Holmes, F. A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S. K. L., Mansi, J., Barrios, C. H., Gnant, M., Tomašević, Z., Denduluri, N., Šeparović, R., Gokmen, E., Bashford, A., Ruiz Borrego, M., Kim, S.-B., Jakobsen, E. H., … Chan, A. (2017). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 18(12), 1688–1700. https://doi.org/10.1016/S1470-2045(17)30717-9

Chicago

Martin, Miguel, Frankie A Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, et al. 2017. “Neratinib after Trastuzumab-Based Adjuvant Therapy in HER2-Positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” The Lancet. Oncology 18 (12): 1688–1700. doi:10.1016/S1470-2045(17)30717-9.